dm+d

Unassigned

New Medicines

Relapsing-remitting multiple sclerosis (RRMS)

Information

New molecular entity
Immunic Therapeutics AG
Immunic Therapeutics AG

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Inhibits the enzyme dihydroorotate dehydrogenase (DHODH) which leads to reduced pro-inflammatory cytokine release including IL-17 (IL-17A and IL-17F) and interferon gamma (IFNg) by stimulated T-cells, and causes induction of apoptosis in activated lymphocytes. [2]
MS estimated prevalence is 190 cases per 100,000 population. MS is more than twice as common in females than males. The highest prevalence for MS occurs in the 60 to 69 years age group for both sexes. The MS estimated incidence in England is between 8 and 11 new cases per 100,000 population [1].
Relapsing-remitting multiple sclerosis (RRMS)
Oral